Literature DB >> 14604970

Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells.

Fiona J Clark1, Richard Gregg, Karen Piper, Debbie Dunnion, Lisa Freeman, Mike Griffiths, Gulnaz Begum, Premini Mahendra, Charles Craddock, Paul Moss, Ronjon Chakraverty.   

Abstract

Chronic graft-versus-host disease (cGVHD) is characterized by a state of profound immunodeficiency in association with alloreactive and autoimmune phenomena. These observations indicate an impairment of immunologic tolerance that could involve both central and peripheral mechanisms. Defective thymic function may contribute to dysregulation of central tolerance, but few studies have addressed peripheral tolerance. Recently a population of CD4+CD25+ T cells (Treg cells) has been characterized, which controls immunologic reactivity in vivo and which on transfer can prevent experimental acute GVHD. We investigated the number and function of peripheral blood CD4+CD25high T cells in patients more than 100 days after allogeneic hematopoietic stem cell transplantation. Patients with cGVHD had markedly elevated numbers of CD4+CD25high T cells as compared to patients without GVHD. CD4+CD25high T cells derived from patients in both groups were of donor origin, lacked markers of recent activation, and expressed intracellular CD152. In contrast to controls, CD4+CD25high T cells derived from patients with cGVHD were characterized by lower surface CD62L expression. In vitro, CD4+CD25high T cells were hyporesponsive to polyclonal stimulation and suppressed the proliferation and cytokine synthesis of CD4+CD25- cells, an effect that was independent of interleukin 10. These results indicate that chronic graft-versus-host injury does not occur as a result of Treg cell deficiency.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14604970     DOI: 10.1182/blood-2003-06-2073

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

1.  Impaired regulatory T cell reconstitution in patients with acute graft-versus-host disease and cytomegalovirus infection after allogeneic bone marrow transplantation.

Authors:  Alain M Ngoma; Kazuhiko Ikeda; Yuko Hashimoto; Kazuhiro Mochizuki; Hiroshi Takahashi; Hideki Sano; Hayato Matsumoto; Hideyoshi Noji; Syunnichi Saito; Atsushi Kikuta; Kazuei Ogawa; Mikio Ohtsuka; Masafumi Abe; Kenneth E Nollet; Hitoshi Ohto
Journal:  Int J Hematol       Date:  2011-12-14       Impact factor: 2.490

Review 2.  Regulatory immune cells in transplantation.

Authors:  Kathryn J Wood; Andrew Bushell; Joanna Hester
Journal:  Nat Rev Immunol       Date:  2012-05-25       Impact factor: 53.106

3.  High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT.

Authors:  Katayoun Rezvani; Stephan Mielke; Mojgan Ahmadzadeh; Yasemin Kilical; Bipin N Savani; Josette Zeilah; Keyvan Keyvanfar; Aldemar Montero; Nancy Hensel; Roger Kurlander; A John Barrett
Journal:  Blood       Date:  2006-04-20       Impact factor: 22.113

4.  Blood and gastric FOXP3+ T cells are not decreased in human gastric graft-versus-host disease.

Authors:  James D Lord; Robert C Hackman; Ted A Gooley; Brent L Wood; Amanda C Moklebust; David M Hockenbery; Gideon Steinbach; Steven F Ziegler; George B McDonald
Journal:  Biol Blood Marrow Transplant       Date:  2010-09-24       Impact factor: 5.742

Review 5.  Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells.

Authors:  Carol H Miao
Journal:  Expert Rev Hematol       Date:  2010-08       Impact factor: 2.929

6.  Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion.

Authors:  James W Hart; Lisa H Shiue; Elizabeth J Shpall; Amin M Alousi
Journal:  Ther Adv Hematol       Date:  2013-10

Review 7.  The search for drug-targetable diagnostic, prognostic and predictive biomarkers in chronic graft-versus-host disease.

Authors:  Hong-Gang Ren; Djamilatou Adom; Sophie Paczesny
Journal:  Expert Rev Clin Immunol       Date:  2018-04-19       Impact factor: 4.473

Review 8.  Oral graft-versus-host disease.

Authors:  M M Imanguli; I Alevizos; R Brown; S Z Pavletic; J C Atkinson
Journal:  Oral Dis       Date:  2008-07       Impact factor: 3.511

Review 9.  Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?

Authors:  Celalettin Ustun; Jeffrey S Miller; David H Munn; Daniel J Weisdorf; Bruce R Blazar
Journal:  Blood       Date:  2011-08-31       Impact factor: 22.113

10.  Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302.

Authors:  Javier Bolaños-Meade; Juan Wu; Brent R Logan; John E Levine; Vincent T Ho; Amin M Alousi; Daniel J Weisdorf; Leo Luznik
Journal:  Biol Blood Marrow Transplant       Date:  2012-12-12       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.